Neural tissue engineering

Biomaterials for Tissue Engineering Applications: A Review of the Past and Future Trends

Volumn , Issue , 2011, Pages 489-510

  Lavik, Erin ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Drug delivery; Nerve grafts; Stem cells; Translation

Indexed keywords

EID: 84886139510     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-7091-0385-2_17     Document Type: Chapter

References (138)

1. Whittemore S. Lecture at the Kentucky Trust for Spinal Cord Regeneration Conference, 1997.
2. Chen ZL, Yu WM, Strickland S. Peripheral regeneration. Annu Rev Neurosci 2007;30:209-233.
3. Chang AS, Yannas IV. Peripheral Nerve Regeneration. In: Smith B, Adelman G, editors. Neuroscience Year, Supplement to the Enclyclopedia of Neuroscience, 1992. p. 125-126.
4. Malik RA. Current and future strategies for the management of diabetic neuropathy. Treat Endocrinol 2003;2(6):389-400.
5. Beattie MS, Bresnaan JC, Komon J, Tovar CA, Meter MV, Anderson DK, et al. Endogenous repair after spinal cord contusion injuries in the rat. Exp Neurol 1997;148:453-463.
6. Siemionow M, Sonmez E. Nerve allograft transplantation: a review. J Reconstr Microsurg 2007;23(8):511-520.
7. Mackinnon SE, Dellon A. Surgery of the Peripheral Nerve. New York: Thieme Medical Publishers, 1988.
8. Midha R, Mackinnon SE, Becker LE. The fate of Schwann cells in peripheral nerve allografts. J Neuropathol Exp Neurol 1994;53(3):316-322.
9. Livshits A, Catz A, Folman Y, Witz M, Livshits V, Baskov A, et al. Reinnervation of the neurogenic bladder in the late periodof the spinal cord trauma. Spinal Cord 2004;42(4):211-217.
10. Tadie M, Liu S, Robert R, Guiheneuc P, Pereon Y, Perrouin-Verbe B, et al. Partial return of motor function in paralyzed legs after surgical bypass of the lesion site by nerve autografts three years after spinal cord injury. J Neurotrauma 2002;19(8):909-916.
11. Oppenheim JS, Spitzer DE, Winfree CJ. Spinal cord bypass surgery using peripheral nerve transfers: review of translational studies and a case report on its use following complete spinal cord injury in a human. Experimental article. Neurosurg Focus 2009;26(2):E6.
12. Cheng H, Cao Y, and Olson, L. Spinal Cord Repair in Adult Paraplegic Rats: Partial Restoration of Hind Limb Function. Science 1996;273:510-513.
13. Huang W, Chuang T, Liao K, Shih Y, Lee L, Cheng H. Prospective Study of Nerve Repair in Patients with Chronic Cervical Spinal Injury. Washington, DC: Society for Neuroscience, 2005.
14. Gilbert TW, Sellaro TL, Badylak SF. Decellularization of tissues and organs. Biomaterials 2006;27(19):3675-3683.
15. Hudson TW, Zawko S, Deister C, Lundy S, Hu CY, Lee K, et al. Optimized acellular nerve graft is immunologically tolerated and supports regeneration. Tissue Eng 2004;10(11-12):1641-1651.
16. Whitlock EL, Tuffaha SH, Luciano JP, Yan Y, Hunter DA, Magill CK, et al. Processed allografts and type I collagen conduits for repair of peripheral nerve gaps. Muscle Nerve 2009;39(6):787-799.
17. Chamberlain LJ, Yannas IV, Hsu HP, Strichartz G, Spector M. Collagen-GAG substrate enhances the quality of nerve regeneration through collagen tubes up to level of autograft. Exp Neurol 1998;154(2):315-329.
18. Lundborg G, Rosen B, Dahlin L, Holmberg J, Rosen I. Tubular repair of the median or ulnar nerve in the human forearm: a 5-year follow-up. J Hand Surg Br 2004;29(2):100-107.
19. Dahlin LB, Lundborg G. Use of tubes in peripheral nerve repair. Neurosurg Clin N Am 2001;12(2):341-352.
20. Dahlin LB, Anagnostaki L, Lundborg G. Tissue response to silicone tubes used to repair human median and ulnar nerves. Scand J Plast Reconstr Surg Hand Surg 2001;35(1):29-34.
21. Wangensteen KJ, Kalliainen LK. Collagen Tube Conduits in Peripheral Nerve Repair: A Retrospective Analysis. Hand (N Y) 2009 Nov. 24.
22. Meyer RA, Bagheri SC. A bioabsorbable collagen nerve cuff (NeuraGen) for repair of lingual and inferior alveolar nerve injuries: a case series. J Oral Maxillofac Surg 2009;67(11):2550-2551.
23. Barnett SC. Olfactory ensheathing cells: unique glial cell types? J Neurotrauma 2004;21(4):375-382.
24. Au WW, Treloar HB, Greer CA. Sublaminar organization of the mouse olfactory bulb nerve layer. J Comp Neurol 2002;446(1):68-80.
25. Kawaja MD, Boyd JG, Smithson LJ, Jahed A, Doucette R. Technical strategies to isolate olfactory ensheathing cells for intraspinal implantation. J Neurotrauma 2009;26(2):155-177.
26. Huang H, Chen L, Wang H, Xiu B, Li B, Wang R, et al. Influence of patients' age on functional recovery after transplantation of olfactory ensheathing cells into injured spinal cord injury. Chin Med J (Engl) 2003;116(10):1488-1491.
27. Dobkin BH, Curt A, Guest J. Cellular transplants in China: observational study from the largest human experiment in chronic spinal cord injury. Neurorehabil Neural Repair 2006;20(1):5-13.
28. Cyranoski D. Patients warned about unproven spinal surgery. Nature 2006;440(7086):850-851.
29. Judson H. The problematical Dr. Huang Hongyun. Technol Rev 2005;5(1):1-5.
30. Chew S, Khandji AG, Montes J, Mitsumoto H, Gordon PH. Olfactory ensheathing glia injections in Beijing: misleading patients with ALS. Amyotroph Lateral Scler 2007;8(5):314-316.
31. Fawcett JW, Curt A, Steeves JD, Coleman WP, Tuszynski MH, Lammertse D, et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord 2007;45(3):190-205.
32. Cyranoski D. Chinese network to start trials of spinal surgery. Nature 2007;446(7135):476-477.
33. Mackay-Sim A, Feron F, Cochrane J, Bassingthwaighte L, Bayliss C, Davies W, et al. Autologous olfactory ensheathing cell transplantation in human paraplegia: a 3-year clinical trial. Brain 2008;131(Pt 9):2376-2386.
34. Taupin P. HuCNS-SC stemcells. Curr Opin Mol Ther 2006;8(2):156-163.
35. Cooper JD. Moving towards therapies for juvenile Batten disease? Exp Neurol 2008;211(2):329-331.
36. Martin RA, Robert JS. Is risky pediatric research without prospect of direct benefit ever justified? Am J Bioeth 2007;7(3):12-15.
37. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006;7(1):41-53.
38. Rite I, Machado A, Cano J, Venero JL. Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons. J Neurochem 2007;101(6):1567-1582.
39. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008;57(2):178-201.
40. Zünkeler B, Carson R, Olson J, Blasberg R, DeVroom H, Lutz R, et al. Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J Neurosurg 1996;85(6):1056-1065.
41. Bracken MB, Shepard M, Holford T, Leosummers L, Aldrich E, Fazl M, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. JAMA 1997;277:1597-1604.
42. Hawryluk GW, Rowland J, Kwon BK, Fehlings MG. Protection and repair of the injured spinal cord: a review of completed, ongoing, and planned clinical trials for acute spinal cord injury. Neurosurg Focus 2008;25(5):E14.
43. Dang WB, Daviau T, Ying P, Zhao Y, Nowotnik D, Clow CS, et al. Effects of GLIADEL (R) wafer initial molecular weight on the erosion of wafer and release of BCNU. J Control Release 1996;42(1):83-92.
44. Attenello FJ, Mukherjee D, Datoo G, McGirt MJ, Bohan E, Weingart JD, et al. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 2008;15(10):2887-2893.
45. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10(5):459-466.
46. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003;9(5):589-595.
47. GDNF poses troubling questions for doctors, drug maker. Toxicity, negative outcome raise doubts. Ann Neurol 2006;59(3):A5-6.
48. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006;59(3):459-466.
49. Corcia P, Meininger V. Management of amyotrophic lateral sclerosis. Drugs 2008;68(8):1037-1048.
50. Al-Shahi Salman R. Haemostatic drug therapies for acute spontaneous intracerebral haemorrhage. Cochrane Database Syst Rev 2009(4): CD005951.
51. Wardlaw JM, Murray V, Berge E, Del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2009(4): CD000213.
52. Nakamura M, Bregman BS. Differences in neurotrophic factor gene expression profiles between neonate and adult rat spinal cord after injury. Exp Neurol 2001;169(2):407-415.
53. Widenfalk J, Lundstromer K, Jubran M, Brene S, Olson L. Neurotrophic factors and receptors in the immature and adult spinal cord after mechanical injury or kainic acid. J Neurosci 2001;21(10):3457-3475.
54. Khan T, Dauzvardis M, Sayers S. Carbon filament implants promote axonal growth across the transected rat spinal cord. Brain Res 1991;541:139-145.
55. Marchand R, Woerly S. Transected spinal cords grafted with in situ self-assembled collagen matrices. Neuroscientist 1990;36:45-60.
56. Guest JD, Hesse D, Schnell L, Schwab ME, Bunge MB, Bunge RP. Influence of IN-1 antibody and acidic FGF-fibrin glue on the response of injured corticospinal tract axons to human Schwann cell grafts. J Neurosci Res 1997;50:888-905.
57. Guest JD, Rao A, Olson L, Bunge MB, Bunge RP. The ability of human Schwann cell grafts to promote regeneration in the transected nude rat spinal cord. Exp Neurol 1997;148:502-522.
58. Ramón-Cueto A, Cordero MI, Santos-Benito FF, Avila J. Functional recovery of paraplegic rats and motor axon regeneration in their spinal cords by olfactory ensheathing glia. Neuron 2000;25:425-435.
59. Xu XM, Guénard V, Kleitman N, Bunge MB. Axonal regeneration into Schwann cellseeded guidance channels grafted into transected adult rat spinal cord. J Comp Neurol 1995;351:145-160.
60. Xu XM, Guénard V, Kleitman N, Aebischer P, Bunge MB. A combination of BDNF and NT-3 promotes supraspinal axonal regeneration into Schwann Cell grafts in adult rat thoracic spinal cord. Exp Neurol 1995;134:261-272.
61. Gautier SE, Oudega M, Fragoso M, Chapon P, Plant GW, Bunge MB, et al. Poly (a-hydroxyacids) for application in the spinal cord: resorbability and biocompatability with adult rat Schwann cells and spinal cord. J Biomed Mater Res 1998;42:642-654.
62. Xu XM, Chen A, Guénard V, Kleitman N, Bunge MB. Bridging Schwann cell transplants promote axonal regeneration from both the rostral and caudal stumps of the transected adult rat spinal cord. J Neurocytol 1997;26:1-16.
63. Xu X, Zhang S-X, Li H, Aebischer P, Bunge M. Regrowth of axons into the distal spinal cord through a Schwann-cell-seeded mini-channel implanted into hemisected adult rat spinal cord. Eur J Neurosci 1999;11:1723-1740.
64. Chen A, Xu XM, Kleitman N, Bunge MB. Methylprednisolone administration improves axonal regeneration into Schwann cell grafts in transected adult rat thoracic spinal cord. Exp Neurol 1996;138:261-276.
65. Schwab ME, and Caroni, P. Oligodendrocytes and CNS myelin are nonpermissive substrates for neurite growth and fibroblast spreading in vitro. J Neurosci 1988;8:2381-2393.
66. Schnell L, Schwab ME. Axonal regeneration in the rat spinal cord produced by an antibody against myelin-associated neurite growth inhibitors. Nature 1990;343:269-272.
67. Brosamle C, Huber AB, Fiedler M, Skerra A, Schwab ME. Regeneration of lesioned corticospinal tract fibers in the adult rat induced by a recombinant, humanized IN-1 antibody fragment. J Neurosci 2000;20:8061-8068.
68. Bregman BS, Kunkel-Bagden E, Schnell L, Dai HN, Gao D, Schwab ME. Recovery from spinal cord injury mediated by antibodies to neurite growth inhibitors. Nature 1995;378:498-501.
69. Meyenburg JV, Brøsamle C, Metz GAS, Schwab ME. Regeneration and sprouting of chronically injured corticospinal tract fibers in adult rats promoted by NT-3 and the mAb IN-1, which neutralizes myelin-associated neurite growth inhibitors. Exp Neurol 1998;154:583-594.
70. Davies SJ, Fitch MT, Memberg SP, Hall AK, Raisman G, Silver J. Regeneration of adult axons in white matter tracts of the central nervous system. Nature 1997;390:680-683.
71. Davies SJA, Goucher DR, Doller C, Silver J. Robust regeneration of adult sensory axons in degenerating white matter of the adult rat spinal cord. J Neurosci 1999;19:5810-5822.
72. Osterholm JL. The pathological response to spinal cord injury. J Neurosurg 1974;40:5-33.
73. Properzi F, Asher R, Fawcett J. Chondroitin sulphate proteoglycans in the central nervous system: changes and synthesis after injury. Biochem Soc Trans 2003;31(2):335-336.
74. Rhodes K, Fawcett J. Chondroitin sulphate proteoglycans: preventing plasticity or protecting the CNS? J Anat 2004;204(1):33-48.
75. Silver J, Miller JH. Regeneration beyond the glial scar. Nat Rev Neurosci 2004;5(2):146-156.
76. Pearse DD, Pereira FC, Marcillo AE, Bates ML, Berrocal YA, Filbin MT, et al. cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury. Nat Med 2004;10(6):610-616.
77. Fouad K, Schnell L, Bunge MB, Schwab ME, Liebscher T, Pearse DD. Combining Schwann cell bridges and olfactory-ensheathing glia grafts with chondroitinase promotes locomotor recovery after complete transection of the spinal cord. J Neurosci 2005;25(5):1169-1178.
78. Saunders NR, Kitchener P, Knott GW, Nicholls JG, Potter A, Smith TJ. Development of walking, swimming and neuronal connections after complete spinal cord transection in the neonatal opossum Monodelphis domestica. J Neurosci 1998;18:339-355.
79. Jakeman LB, Reier PJ. Axonal projections between fetal spinal cord transplants and the adult rat spinal cord: a neuroanatomical tracing study of local interactions. J Comp Neurol 1991;307:311-334.
80. Bregman BS, McAtee M, Dai HN, Kuhn PL. Neurotrophic factors increase axonal growth after spinal cord injury and transplantation in the adult rat. Exp Neurol 1997;148:475-494.
81. Coumans J, Lin TT-S, Dai H, MacArthur L, McAtee M, Nash C, et al. Axonal regeneration and functional recovery after complete spinal cord transection in rats by delayed treatment with transplants and neurotrophins. J Neurosci 2001;21:9334-9344.
82. Barinaga M. Fetal neuron grafts pave the way for stem cell therapies. Science 2000;287:1421-1422.
83. Gage FH. Mammalian neural stem cells. Science 2000;287:1433-1438.
84. Nishida A, Takahashi M, Tanihara H, Nakano I, Takahashi JB, Mizoguchi A, et al. Incorporation and differentiation of hippocampus-derived neural stem cells transplanted in injured adult rat retina. Invest Ophthalmol Vis Sci 2000;41(13):4268-4274.
85. Kurimoto Y, Shibuki H, Kaneko Y, Ichikawa M, Kurokawa T, Takahashi M, et al. Transplantation of adult rat hippocampus-derived neural stem cells into retina injured by transient ischemia. Neurosci Lett 2001;306(1-2):57-60.
86. Isacson O, Deacon TW, Pakzaban P, Galpern WR, Dinsmore J, Burns LH. Transplanted xenogenic neural cells in neurodegenerative disease models exhibit remarkable axonal target specificity and distinct growth patterns of glial and axonal fibres. Nat Med 1995;1:1189-1194.
87. Castilho R, Hansson O, Brundin P. Improving the survival of grafted embryonic dopamine neurons in rodent models of Parkinson's disease. Prog Brain Res 2000;127:203-231.
88. Armstrong RJE, Tyers P, Jain M, Richards A, Dunnett SB, Rosser AE, et al. Transplantation of expanded neural precursor cells from the developing pig ventral mesencephalon in a rat model of Parkinson's disease. Exp Brain Res 2003;151(2):204-217.
89. Ogawa Y, Sawamoto K, Miyata T, Miyao S, Watanabe M, Nakamura M, et al. Transplantation of in vitro-expanded fetal neural progenitor cells results in neurogenesis and functional recovery after spinal cord contusion injury in adult rats. J Neurosci Res 2002;69(6):925-933.
90. Pluchino S, Quattrini A, Brambilla E, Gritti A, Salani G, Dina G, et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 2003;422(6933):688-694.
91. Onifer SM, Cannon AB, Whittemore SR. Altered differentiation of CNS neural progenitor cells after transplantation into the injured adult rat spinal cord. Cell Transplant 1997;6:327-338.
92. Park K, Liu S, Flax J, Nissim S, Stieg P, Snyder E. Transplantation of neural progenitor and stem cells: developmental insights may suggest new therapies for spinal cord and other CNS dysfunction. J Neurotrauma 1999;16:675-687.
93. Cao Q, Zhang YP, Howard RM, Walters WM, Tsoulfas P, Wittemore SR. Pluripotent stem cells engrafted into the normal or lesioned adult rat spinal cord are restricted to a glial lineage. Exp Neurol 2001;167:48-58.
94. Pfrieger FW, Barres BA. Synaptic efficacy enhanced by glial cells in vitro. Science 1997;277:1684-1687.
95. Liu S, Qu Y, Stewart TJ, Howard MJ, Chakrabortty S, Holekamp TF, et al. Embryonic Stem Cells Differentiate into Oligodendrocytes and Myelinate in Culture and After Spinal Cord Transplantation. Proc Natl Acad Sci U S A 2000;97:6126-6131.
96. Jeffery ND, Crang AJ, O'Leary MT, Hodge SJ, Blakemore WF. Behavioral Consequences of oligodendrocyte progenitor cell transplantation into experimental demyelinating lesions in the rat spinal cord. Eur J Neurosci 1999;11:1508-1514.
97. Akiyama Y, Honmou O, Kato T, Uede T, Hashi K, Kocsis JD. Transplantation of clonal neural precursor cells derived from adult human brain establishes functional peripheral myelin in the rat spinal cord. Exp Neurol 2001;167:27-39.
98. Einstein O, Ben-Menachem-Tzidon O, Mizrachi-Kol R, Reinhartz E, Grigoriadis N, Ben-Hur T. Survival of neural precursor cells in growth factor-poor environment: implications for transplantation in chronic disease. Glia 2006;53(4):449-455.
99. Okano H, Ogawa Y, Nakamura M, Kaneko S, Iwanami A, Toyama Y. Transplantation of neural stem cells into the spinal cord after injury. Semin Cell Dev Biol 2003;14(3):191-198.
100. Tomita M, Lavik E, Klassen H, Zahir T, Langer R, Young MJ. Biodegradable polymer composite grafts promote the survival and differentiation of retinal progenitor cells. Stem Cells 2005;23(10):1579-1588.
101. Silva GA, Czeisler C, Niece KL, Beniash E, Harrington DA, Kessler JA, et al. Selective differentiation of neural progenitor cells by high-epitope density nanofibers. Science 2004;303(5662):1352-1355.
102. Yang F, Murugan R, Wang S, Ramakrishna S. Electrospinning of nano/micro scale poly (L-lactic acid) aligned fibers and their potential in neural tissue engineering. Biomaterials 2005;26(15):2603-2610.
103. Matthews RT, Kelly GM, Zerillo CA, Gray G, Tiemeyer M, Hockfield S. Aggrecan glycoforms contribute to the molecular heterogeneity of perineuronal nets. J Neurosci 2002;22(17):7536-7547.
104. Kabos P, Matundan H, Zandian M, Bertolotto C, Robinson ML, Davy BE, et al. Neural precursors express multiple chondroitin sulfate proteoglycans, including the lectican family. Biochem Biophys Res Commun 2004;318(4):955-963.
105. Pan L, Ren Y, Cui F, Xu Q. Viability and differentiation of neural precursors on hyaluronic acid hydrogel scaffold. J Neurosci Res 2009;87(14):3207-3220.
106. Cao H, Liu T, Chew SY. The application of nanofibrous scaffolds in neural tissue engineering. Adv Drug Deliv Rev 2009;61(12):1055-1064.
107. Carlberg B, Axell MZ, Nannmark U, Liu J, Kuhn HG. Electrospun polyurethane scaffolds for proliferation and neuronal differentiation of human embryonic stem cells. Biomed Mater 2009;4(4):45004.
108. Yao L, O'Brien N, Windebank A, Pandit A. Orienting neurite growth in electrospun fibrous neural conduits. J Biomed Mater Res B Appl Biomater 2009;90(2):483-491.
109. Wang HB, Mullins ME, Cregg JM, Hurtado A, Oudega M, Trombley MT, et al. Creation of highly aligned electrospun poly-L-lactic acid fibers for nerve regeneration applications. J Neural Eng 2009;6(1):016001.
110. Anseth KS, Metters AT, Bryant SJ, Martens PJ, Elisseeff JH, Bowman CN. In situ forming degradable networks and their application in tissue engineering and drug delivery. J Control Release 2002;78(1-3):199-209.
111. Hynes SR, Rauch MF, Bertram J, Lavik EB. A library of tunable poly (ethylene glycol)/poly-L-lysine hydrogels to investigate the materials cues that influence neural stem cell differentiation. J Biomed Mater Res A 2009;89(2):499-509.
112. Ma W, Fitzgerald W, Liu QY, O'Shaughnessy TJ, Maric D, Lin HJ, et al. CNS stem and progenitor cell differentiation into functional neuronal circuits in three-dimensional collagen gels. Exp Neurol 2004;190(2):276-288.
113. Teixeira AI, Duckworth JK, Hermanson O. Getting the right stuff: controlling neural stem cell state and fate in vivo and in vitro with biomaterials. Cell Res 2007;17(1):56-61.
114. Banerjee A, Arha M, Choudhary S, Ashton RS, Bhatia SR, Schaffer DV, et al. The influence of hydrogel modulus on the proliferation and differentiation of encapsulated neural stem cells. Biomaterials 2009;30(27):4695-4699.
115. Saha K, Keung AJ, Irwin EF, Li Y, Little L, Schaffer DV, et al. Substrate modulus directs neural stem cell behavior. Biophys J 2008;95(9):4426-4438.
116. Jiang FX, Yurke B, Firestein BL, Langrana NA. Neurite outgrowth on a DNA crosslinked hydrogel with tunable stiffnesses. Ann Biomed Eng 2008;36(9):1565-1579.
117. Engler AJ, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem cell lineage specification. Cell 2006;126(4):677-689.
118. Woerly S, Pinet E, de Robertis L, Van Diep D, Bousmina M. Spinal cord repair with PHPMA hydrogel containing RGD peptides (NeuroGel (TM)). Biomaterials 2001;22(10):1095-1111.
119. Woerly S, Doan VD, Sosa N, de Vellis J, Espinosa-Jeffrey A. Prevention of gliotic scar formation by NeuroGel (TM) allows partial endogenous repair of transected cat spinal cord. J Neurosci Res 2004;75(2):262-272.
120. Teng YD, Lavik EB, Qu X, Park KI, Ourednik J, Zurakowski D, et al. Functional recovery following traumatic spinal cord injury mediated by a unique polymer scaffold seeded with neural stem cells. Proc Natl Acad Sci U S A 2002;99(5):3024-3029.
121. Tsai EC, Dalton PD, Shoichet MS, Tator CH. Synthetic hydrogel guidance channels facilitate regeneration of adult rat brainstem motor axons after complete spinal cord transection. J Neurotrauma 2004;21(6):789-804.
122. Tsai EC, Dalton PD, Shoichet MS, Tator CH. Matrix inclusion within synthetic hydrogel guidance channels improves specific supraspinal and local axonal regeneration after complete spinal cord transection. Biomaterials 2006;27(3):519-533.
123. Johnson PJ, Parker SR, Sakiyama-Elbert SE. Fibrin-based tissue engineering scaffolds enhance neural fiber sprouting and delay the accumulation of reactive astrocytes at the lesion in a subacute model of spinal cord injury. J Biomed Mater Res A 2010;92(1):152-163.
124. Tysseling-Mattiace VM, Sahni V, Niece KL, Birch D, Czeisler C, Fehlings MG, et al. Selfassembling nanofibers inhibit glial scar formation and promote axon elongation after spinal cord injury. J Neurosci 2008;28(14):3814-3823.
125. Woerly S, Doan VD, Evans-Martin F, Paramore CG, Peduzzi JD. Spinal cord reconstruction using NeuroGel implants and functional recovery after chronic injury. J Neurosci Res 2001;66(6):1187-1197.
126. Piantino J, Burdick JA, Goldberg D, Langer R, Benowitz LI. An injectable, biodegradable hydrogel for trophic factor delivery enhances axonal rewiring and improves performance after spinal cord injury. Exp Neurol 2006;201(2):359-367.
127. Taylor SJ, McDonald JW, Sakiyama-Elbert SE. Controlled release of neurotrophin-3 from fibrin gels for spinal cord injury. J Control Release 2004;98(2):281-294.
128. Jain A, Kim YT, McKeon RJ, Bellamkonda RV. In situ gelling hydrogels for conformal repair of spinal cord defects, and local delivery of BDNF after spinal cord injury. Biomaterials 2006;27(3):497-504.
129. Park J, Lim E, Back S, Na H, Park Y, Sun K. Nerve regeneration following spinal cord injury using matrix metalloproteinase-sensitive, hyaluronic acid-based biomimetic hydrogel scaffold containing brain-derived neurotrophic factor. J Biomed Mater Res A 2010;93(3):1091-1099.
130. Patist CM, Mulder MB, Gautier SE, Maquet V, Jerome R, Oudega M. Freeze-dried poly (D, L-lactic acid) macroporous guidance scaffolds impregnated with brain-derived neurotrophic factor in the transected adult rat thoracic spinal cord. Biomaterials 2004;25(9):1569-1582.
131. Stokols S, Tuszynski MH. Freeze-dried agarose scaffolds with uniaxial channels stimulate and guide linear axonal growth following spinal cord injury. Biomaterials 2006;27(3):443-451.
132. Iannotti C, Li HY, Yan P, Lu XB, Wirthlin L, Xu XM. Glial cell line-derived neurotrophic factor-enriched bridging transplants promote propriospinal axonal regeneration and enhance myelination after spinal cord injury. Exp Neurol 2003;183(2):379-393.
133. Kurakhmaeva KB, Djindjikhashvili IA, Petrov VE, Balabanyan VU, Voronina TA, Trofimov SS, et al. Brain targeting of nerve growth factor using poly (butyl cyanoacrylate) nanoparticles. J Drug Target 2009;17(8):564-574.
134. Ren T, Xu N, Cao C, Yuan W, Yu X, Chen J, et al. Preparation and therapeutic efficacy of polysorbate-80-coated amphotericin B/PLA-b-PEG nanoparticles. J Biomater Sci Polym Ed 2009;20(10):1369-1380.
135. Denora N, Trapani A, Laquintana V, Lopedota A, Trapani G. Recent advances in medicinal chemistry and pharmaceutical technology -strategies for drug delivery to the brain. Curr Top Med Chem 2009;9(2):182-196.
136. Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs 2009;23(1):35-58.
137. Tiwari SB, Amiji MM. A review of nanocarrier-based CNS delivery systems. Curr Drug Deliv 2006;3(2):219-232.
138. Roney C, Kulkarni P, Arora V, Antich P, Bonte F, Wu A, et al. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J Control Release 2005 28; 108 (2-3):193-214.